• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Ritonavir

Product ID R3577
Cas No. 155213-67-5
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $76.70 In stock
250 mg $153.30 In stock
1 g $421.70 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ritonavir is an HIV protease inhibitor that is commonly used as a component of highly active anti-retroviral therapy (HAART) in the treatment of HIV infection. Ritonavir exhibits antiviral, anti-angiogenic, neuroprotective, and hyperlipidemic activities. Ritonavir inhibits expression of VEGF and HIF-1α, decreasing proliferation in retinal epithelial cells and indicating potential use as a treatment for ocular diseases. Ritonavir also inhibits translocation of apoptosis-inducing factor (AIF), activates caspase 9, and inhibits permeability alterations in the mitochondrial membrane potential, preventing apoptosis in retinal photoreceptor cells and macrophages. This compound decreases levels of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and intracellular Ca2+, increasing endoplasmic reticular stress and injury. Additionally, ritonavir increases levels of IL-6 and decreases levels of adiponectin, GLUT4, and fatty acid synthase, inhibiting lipogenesis and increasing lipodystrophy; this compound also increases levels of VLDL.

Product Info

Cas No.

155213-67-5

Purity

≥98%

Formula

C37H48N6O5S2

Formula Wt.

720.95

IUPAC Name

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1, 3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1, 6-diphenylhexan-2-yl]carbamate

Synonym

Norvir, A-84538, ABT-538, NSC693184, RTV

Melting Point

120-123°C

Solubility

DMSO to 10 mg/mL, Ethanol to 3 mg/mL, Methanol

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

R3577 MSDS PDF

Info Sheet

R3577 Info Sheet PDF

Brochures

Antivirals Booklet

References

Vadlapatla RK, Vadlapudi AD, Pal D, et al. Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro. Eye (Lond). 2013 Nov 8. [Epub ahead of print]. PMID: 24202050.

Kao E, Shinohara M, Feng M, et al. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. Hepatology. 2012 Aug;56(2):594-604. PMID: 22407670.

Hisatomi T, Nakazawa T, Noda K, et al. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest. 2008 Jun;118(6):2025-38. PMID: 18497877.

Grigem S, Fischer-Posovszky P, Debatin KM, et al. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm Metab Res. 2005 Oct;37(10):602-9. PMID: 16278782.

Riddle TM, Schildmeyer NM, Phan C, et al. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2002 Sep;43(9):1458-63. PMID: 12235177.

Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther. 1998 Jan-Feb;20(1):2-25. PMID: 9522101.

Kawakami K, Harada T, Yoshihashi Y, et al. Correlation between glass-forming ability and fragility of pharmaceutical compounds. J Phys Chem B. 2015 Apr 9;119(14):4873-4880. PMID: 25781503.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only